A5000700279- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Lymphoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Genomic variations and chromosomal abnormalities
- CAR-T cell therapy research
- Genomics and Rare Diseases
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Renal and related cancers
- Neuroblastoma Research and Treatments
- Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Viral gastroenteritis research and epidemiology
- Tumors and Oncological Cases
- Gastrointestinal Tumor Research and Treatment
- Multiple and Secondary Primary Cancers
- BRCA gene mutations in cancer
- Gastric Cancer Management and Outcomes
- Adolescent and Pediatric Healthcare
- Metastasis and carcinoma case studies
Mayo Clinic in Arizona
2016-2025
WinnMed
2017-2025
Mayo Clinic
2013-2024
At Bristol
2022
Mid Essex Hospital Services NHS Trust
2021
Mayo Clinic in Florida
2020
Smilow Cancer Hospital
2018
Yale Cancer Center
2018
Roswell Park Comprehensive Cancer Center
2018
University of Minnesota Rochester
2015
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on treatment management considerations AYA patients with cancer. Compared older adults cancer, have unique needs regarding treatment, fertility counseling, psychosocial behavioral issues, supportive care services. The complete version of addresses additional aspects caring patients, including risk factors, screening, diagnosis, survivorship.
Abstract Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this first in human trial (NCT00390299), a carcinoembryonic antigen-expressing oncolytic measles derivative (MV-CEA), was administered recurrent GBM patients either at resection cavity (Group A), or, intratumorally on day 1, followed by second dose after tumor 5 B). A total of 22 received study treatment, 9 Group and 13 B. Primary...
The ability to analyze the genomics of malignancies has opened up new possibilities for off-label targeted therapy in cancers that are refractory standard therapy. At Mayo Clinic these efforts organized through Center Individualized Medicine (CIM).Prior GTB, datasets were analyzed and integrated by a team bioinformaticians cancer biologists. Therapeutically actionable mutations identified 65% (92/141) patients tested with 32% (29/92) receiving genomically FDA approved drugs or an independent...
Local control for Ewing sarcoma (ES) has improved in modern studies. However, it is unclear if these gains have also been achieved pelvis tumors. The purpose of this study to evaluate local and survival ES patients treated the era.All diagnosed from 1990 2012 seen at Mayo Clinic were identified. Factors relevant analyzed.The cohort consisted 48 patients. Fifty-two percent had metastatic disease diagnosis. 5-year overall event-free was 73% 65%, respectively, localized disease. cumulative...
Although checkpoint inhibitors have been approved in multiple cancers, they are still under investigation soft tissue sarcoma (STS). We conducted a retrospective review to report the safety, efficacy, and prognostic factors related STS. A sequential cohort of metastatic STS patients from four institutions treated with was assembled. Logistic Cox regression models were applied determine effect patient characteristics, prior treatment, baseline on achieving best overall response complete (CR),...
11503 Background: Collectively, sarcomas have demonstrated less benefit from immunotherapy than many other cancers. Pts with AS limited options, particularly after taxane chemotherapy. Although is a vascular malignancy, anti-VEGF therapies minimal monotherapy clinical activity. Some cutaneous high UV damage signature, but often do not. Cabozantinib (C) multikinase inhibitor that may alter PD-1 expression in regulatory T cells, promoting an immune permissive environment when combined...
Objectives . To assess the clinical features and local control (LC) outcomes in adult patients with localized Ewing Sarcoma (ES). Methods The records of 102 ES disease ≥18 years age seen from 1977 to 2007 were reviewed. Factors relevant prognosis, survival, LC analyzed. Results. 5-year overall survival (OS) event-free (EFS) 60% 52%, respectively, for entire cohort. Treatment era (1977–1992 versus 1993–2007) remained an independent prognostic factor OS on multivariate analysis, improved...
11514 Background: The role of immunotherapy remains uncertain in most sarcomas. We recently showed significant antitumor benefit for cabozantinib (C) with N AS previously treated a taxane. Since chemotherapy-immunotherapy combinations may synergize, and paclitaxel standard care option advanced AS, we hypothesized that P+N would be more effective than P alone. Methods: report Arm 1 (P+N) 2 (P) this open label, multi-arm, phase II study. Pts all had locally advanced/metastatic no prior taxane...
We report a response to pazopanib in 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma addition molecular profiling of his tumor. To our knowledge, this case is the earliest demonstrate activity an oral multi-targeted kinase inhibitor sarcoma. This provides rationale for adding arm SARC024, phase II study regorafenib, another inhibitor, patients liposarcoma, osteosarcoma and Ewing-like sarcomas (NCT02048371). national multi-institutional ongoing.
Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum. Surgical resection the mainstay of treatment; role chemotherapy not well defined. Therefore, we evaluated impact in survival patients with EO.All EO seen at Mayo Clinic between 1990 2014 were assessed. Forty-three included after all archived pathology slides reviewed confirm diagnosis EO.Of 43 patients, 37 had localized disease 6...
Ewing sarcoma (EwS) is a group of bone and soft tissue cancers in children young adults. The EWS-FLI1 protein, the oncogenic driver EwS, fusion FET EWSR1, at its amino terminus, with carboxy terminus transcription factor, FLI1. Since EwS cells have pronounced sensitivity to radiation chemotherapy-induced DNA damage, role repair likely. Here, we demonstrate that causes defect microhomology-mediated end-joining (MMEJ) repair. EWSR1 splicing factor promotes faithful POLQ pre-mRNA, required for...
Abstract Purpose: Soft tissue sarcoma (STS) are rare malignancies with poor prognosis and limited systemic treatment options. We conducted a phase II study to assess the efficacy safety of trabectedin olaparib in patients advanced disease. Patients Methods: STS who received ≥ 1 prior therapy were recruited into two cohorts. Cohort included leiomyosarcoma liposarcoma; 2 other histologies. All (1.1 mg/m2 24-hour infusion every 21 days) (150 mg BID continuously). The was using Simon Minimax...
11549 Background: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm with subset associated unicentric Castleman disease (UCD). However, the impact of CD association on clinicopathologic features and survival outcomes remains unclear. This study aims to elucidate differences in characteristics FDCS without guide future research clinical practice. Methods: We retrospectively analyzed 41 patients seen at Mayo Clinic between January 2000 December 2024. Patients were categorized into...
Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological are needed to inform trial design for testing novel therapeutics. Retrospective from a US-based deidentified clinico-genomic database were analyzed patients treated metastatic DDLPS between 2011 2021. Overall survival (OS), real-world progression-free (rwPFS), time next treatment (TTNT) described in the overall cohort (n = 51) subgroup of with...
This study evaluated the health effects of routine and intensified dental care disease prevention in persons with human immunodeficiency virus (HIV). We recruited 376 HIV-infected ages 19 to 61 CD4 counts between 100 750 into a year-long two-arm randomized controlled trial. Control group subjects (n = 185) received professional protective treatment checkups at baseline, 6 months, 1 year, plus care. Enhanced patients 191) bimonthly twice-daily chlorhexidine mouthrinses treat gingivitis....
11016 Background: P, a VEGFR TKI, is approved for advanced STS based on median PFS (mPFS) in the absence of CR. Endoglin receptor expressed tumor vessels that overexpressed certain STS, particularly angiosarcoma (AS). It upregulated following VEGF inhibition and may mediate resistance to P. We performed phase 1B/2A study TRC105, an endoglin antibody, combination with P pts STS. Methods: The 1 was dose escalation determine RP2D. 2 single arm evaluation TRC105 at RP2D 800 mg/day PO, primary...
Abstract Background In the United States, rare disease (RD) is defined as a condition that affects fewer than 200,000 individuals. Collectively, RD an estimated 30 million Americans. A significant portion of has underlying genetic cause; however, this may go undiagnosed. To better serve these patients, Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) was created under auspices Center Individualized Medicine (CIM) aiming to integrate genomics into subspecialty practice including...